Under the deal, Burning Rock will offer its nucleic acid extraction, library preparation and data analysis software, while Illumina will provide next-generation sequencing (NGS) components and related reagents.
Specifically, both companies will work together to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market.
Burning Rock founder and CEO Yusheng Han said: "We have been working to promote the clinical application of genomic technology in China. Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."
Illumina senior vice-president and chief medical officer Dr Rick Klausner said: "We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome."
Burning Rock also has a molecular and pathological examination platform, comprising NGS, qPCR, IHC, FISH and digital pathology.
Illumina provides DNA sequencing and array-based technologies for customers in the research, clinical and applied markets.
